Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06243406
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-07
First Post:
2024-01-29
Brief Title:
Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization
Sponsor:
Beijing Hospital
Organization:
Beijing Hospital
Study Overview
Official Title:
Study on the Biomarkers to Predict the Response to Anti-vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Choroidal neovascularization CNV also known as subretinal neovascularization is a proliferative change from choroidal capillaries that has become one of the most important causes of blindness worldwide CNV can occur in a variety of fundus diseases including pathologic myopia polypoidal choroidal vasculopathy At present intravitreal injection of anti-vascular endothelial growth factor VEGF drugs is the first-line effective treatment for CNV Although a number of clinical studies have shown that the treatment of CNV with anti-VEGF drugs has achieved good visual and anatomical effects there are still some patients whose CNV has not decreased significantly or even progressed continuously after treatment Rapid advances in imaging technology have made it possible to explore the quantitative and qualitative characteristics of choroid and CNV especially swept source optical coherence tomography angiography SS-OCTA
The objectives are to improve the OCTA typing of CNV and analyze the vascular morphological characteristics of each type to identify the changes in vascular characteristics of CNV after anti-VEGF treatment in vitreous cavity and to elucidate the predictive effects of neovascularization and choroidal vascular characteristics on visual acuity and anatomic effects of vitreous anti-VEGF drug treatment for CNV
The objectives are to improve the OCTA typing of CNV and analyze the vascular morphological characteristics of each type to identify the changes in vascular characteristics of CNV after anti-VEGF treatment in vitreous cavity and to elucidate the predictive effects of neovascularization and choroidal vascular characteristics on visual acuity and anatomic effects of vitreous anti-VEGF drug treatment for CNV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None